Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

2011

Analysis of CD16 + CD56 dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

41

References

48

Citations